Top Markets
#1 DeFiChain DeFiChain +2,516.54%
#2 Akedo Akedo +207.46%
#3 ONFA ONFA +54.25%
#4 Metaplex Metaplex +23.40%
#5 Osaka Protocol Osaka Protocol +21.73%
#6 Talus Network Talus Network +20.44%
#7 Wrapped Krown Wrapped Krown +20.00%
#8 DODO DODO +17.78%
#9 Black Phoenix Black Phoenix +15.09%
#10 eCash eCash +13.30%
Coin of the day
DeFiChain DeFiChain
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Rang in aandelen #16315
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Aandeelprijs
$0.94180721
Marktkapitalisatie
$22.26M
Verandering (1 dag)
0.38%
Verandering (1 jaar)
-14.35%
Land
FR
Handel Valbiotis SA (ALVAL)

Categorie

Healthcare
Winst voor Valbiotis SA (ALVAL)
Winst in Dec 2025 TTM: $-11.05M
Volgens de meest recente financiële verslagen van Valbiotis SA bedraagt de huidige winst van het bedrijf $-11.05M. In 2023 behaalde het bedrijf een winst van $-10.39M, een stijging ten opzichte van de winst van 2022, die $-15.24M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Valbiotis SA van 2015 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-11.05M 6.26%
2024 $-10.40M 0.09%
2023 $-10.39M -31.83%
2022 $-15.24M 28.45%
2021 $-11.86M 91.50%
2020 $-6.19M -17.90%
2019 $-7.54M 32.17%
2018 $-5.71M 94.72%
2017 $-2.93M 369.81%
2016 $-623.95K -40.51%
2015 $-1.05M 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$24.72B -223,839.46%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.17B -46,859.02%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.16B -46,779.37%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -19,450.04%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.48B -13,505.47%
NL